BELGRADE, Mont., Aug. 9, 2012 /PRNewswire/ -- Bacterin International Holdings, Inc. (NYSE MKT: BONE), a leader in the development of revolutionary bone graft material and antimicrobial coatings for medical applications, today announced its financial results for the second quarter ended June 30, 2012:
Management Commentary"We have already achieved 45% of the low end of our annual revenue guidance in the first half of this year," said Guy Cook, CEO of Bacterin. "With our backorder behind us, inventory levels up and planned clean room expansion for 3Q, we expect continuing increased revenues in the second half of 2012 enabling us to achieve our stated 2012 annual revenue guidance. Gross margin of 72% was within our previous guidance and operating expenses decreased from the 1Q of 2012 enabling us to report positive EBITDA for the quarter, and a 54% reduction in EBTIDA loss for the first half of 2012 compared to the prior periods.
"We expect uptake in the wound care market for hMatrix to accelerate next year with the expected issuance of a Q code by January 1, 2013. In the interim, we are gaining traction with our shifted manufacturing and marketing focus, beginning in the second quarter, for hMatrix to address additional markets in sports medicine and reconstructive surgery.
"OsteoSelect DBM putty is gaining sales momentum, leveraging recent animal data equivalency to autologous bone graft, the current gold standard for spinal fusion.
"Data for our coatings remains on track for the second half of this year, as well as independent data on OsteoSponge SC."
2Q 2012 Financial ResultsRevenue for the quarter was $8.2 million compared to $7.8 million in the previous quarter and an increase of 9.3% compared to $7.5 million in the second quarter of 2011. The year over year increase was largely the result of increased sales generated from the Company's direct sales force and independent distributors compared to the second quarter of 2011.
Costs of tissue sales consist primarily of tissue and medical device manufacturing costs. Costs of sales increased by 33.7% to $2.3 million compared to $1.7 million for the three months ended June 30, 2011. The increase was largely the result of increased costs associated with our higher sales. As a percentage of tissue sales, cost of tissue sales was 28% of revenues for the second quarter of 2012 compared to 23% in the comparable prior year period.
Gross profit margin for the quarter was 72%, as compared to 76% in the previous quarter and 77% in the year-ago quarter.
Operating expenses increased 3%, or $179,869, to $6.2 million for the three months ended June 30, 2012 compared to the three months ended June 30, 2011.
General and administrative expenses increased 54%, or $814,686, to$2.3 million, for the three months ended June 30, 2012 compared to the same period of 2011. The increase is primarily due to higher administrative costs supporting the higher revenue in addition to added rental and maintenance expense for increased operational space.
As a percentage of revenue, selling and marketing expenses decreased to 47% in the second quarter of 2012 from 58% in the second quarter of 2011. The decreases were primarily the result of more variable compensation paid to our direct sales force compared to salaries earned in the comparable period of 2011 and a lower corporate sales commission structure.
EBITDA for the quarter totaled $8,000, compared an EBITDA loss of $(541,000) for the previous quarter, and EBITDA of $35,000 for the second quarter of 2011.
YTD 2012 Financial ResultsRevenue for the six months ended June 30 2012 increased 18% to $16.0 million compared to $13.5 million in the first half of 2011. The increase of $2.5 million was largely the result of increased sales generated from our direct sales force and independent distributors compared to the first half of 2011.
Costs of tissue sales consist primarily of tissue and medical device manufacturing costs. Costs of sales increased by 53% or $1.5 million to $4.2 million for the first half of 2012. The increase was largely the result of increased costs associated with our higher sales. As a percentage of tissue sales, cost of tissue sales was 26% of revenues for the second quarter of 2012 compared to 20% in the comparable prior year period.
Gross profit margin was 74%, as compared to 80% in the previous period.
Operating expenses increased 3%, or $414,507, for the six months ended June 30, 2012 compared to the six months ended June 30, 2011.
General and administrative expenses increased 26%, or $1.0 million, to $4.9 million, for the six months ended June 30, 2012 compared to the same period of 2011. The increase is primarily due to higher administrative costs supporting the higher revenue in addition to added rental and maintenance expense for increased operational space.
As a percentage of revenue, selling and marketing expenses decreased to 50% in the second half of 2012 from 64% in the first six months of 2011. The decreases were primarily the result of more variable compensation paid to our direct sales force compared to salaries earned in the comparable period of 2011 and a lower corporate sales commission structure.
EBITDA loss for the first half of 2012 totaled $(527,497) compared an EBITDA loss of $(1.1) million for the comparable period of 2011.
Cash and cash equivalents and net accounts receivable was $7.8 million at June 30, 2012, compared to a total of $9.0 million at March 31, 2012.
"We believe that product constraints were a short term issue we have resolved and that the future and long term opportunity for Bacterin products, in multi-billion dollar addressable markets, remain very strong."Accordingly, we are reiterating our 2012 revenue guidance of $35 to $40 million.
Conference Call Details:Conference Call Details:
Date: Thursday, August 9, 2012
Time: 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time)
Dial-In Number: 1-877-941-1429
Conference ID#: 4557186
The conference call will be broadcast simultaneously and available for replay here and at the investor section of the company's Web site at http://bacterin.com/index.htm.
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact Hayden IR at 1-646-755-7412.
A replay of the call will be available after 7:30 p.m. Eastern Time on the same day and until September 9, 2012.Replay number:1-877-870-5176 International replay number:1-858-384-5517Replay pin number: 4557186
About the Presentation of EBITDAEBITDA is not a financial measure calculated and presented in accordance with U.S. generally accepted accounting principles (GAAP) and should not be considered as an alternative to net income, operating income or any other financial measures so calculated and presented, nor as an alternative to cash flow from operating activities as a measure of liquidity. The company defines EBITDA as net income/(loss) from operations before depreciation, amortization and non-cash stock-based compensation. Other companies (including competitors) may define EBITDA differently. The company presents EBITDA because management believes it to be an important supplemental measure of performance that is commonly used by securities analysts, investors and other interested parties in the evaluation of companies in our industry. Management also uses this information internally for forecasting and budgeting. It may not be indicative of the historical operating results of Bacterin nor is it intended to be predictive of potential future results. Investors should not consider EBITDA in isolation or as a substitute for analysis of the company's results as reported under GAAP. See "GAAP to non-GAAP Reconciliation" below for further information on this non-GAAP measure.
Bacterin International Holdings, Inc.
Reconciliation of Net (Loss) Income From Operations to EBITDA
(Unaudited)Three Months Ended June 30,Six Months Ended June 30,2012201120122011 Net Loss from ops(347,357)(279,997)(1,620,520)(2,216,296) Depreciation95,20662,533214,280115,205 Allocated depreciation94,48694,486188,972188,972 Stock option comp190,055-385,587381,199 Non-cash stock comp(24,069)157,485304,184388,4758,32134,507(527,497)(1,142,445)
About Bacterin International HoldingsBacterin International Holdings, Inc. (NYSE MKT: BONE) develops, manufactures and markets biologics products to domestic and international markets. Bacterin's proprietary methods optimize the growth factors in human allografts to create the ideal stem cell scaffold to promote bone, subchondral repair and dermal growth. These products are used in a variety of applications including enhancing fusion in spine surgery, relief of back pain, promotion of bone growth in foot and ankle surgery, promotion of cranial healing following neurosurgery and subchondral repair in knee and other joint surgeries.
Bacterin's Medical Device division develops, employs, and licenses bioactive coatings for various medical device applications. Bacterin's strategic coating initiatives include antimicrobial coatings designed to inhibit biofilm formation and microbial contamination. For further information, please visit www.bacterin.com.
Important Cautions Regarding Forward-looking StatementsThis news release contains certain disclosures that may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to significant risks and uncertainties. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "continue," "efforts," "expects," "anticipates," "intends," "plans," "believes," "estimates," "projects," "forecasts," "strategy," "will," "goal," "target," "prospects," "potential," "optimistic," "confident," "likely," "probable" or similar expressions or the negative thereof. Statements of historical fact also may be deemed to be forward-looking statements. We caution that these statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the Company's ability to launch beta and full product releases, the Company's ability to obtain FDA concurrence use for anti-microbial coatings in a timely manner; the Company's ability to meet its obligations under existing and anticipated contractual obligations; the Company's ability to develop, market, sell and distribute desirable applications, products and services and to protect its intellectual property; the ability of the Company's sales force to achieve expected results; the ability of the Company's customers to pay and the timeliness of such payments, particularly during recessionary periods; the Company's ability to obtain financing as and when needed; changes in consumer demands and preferences; the Company's ability to attract and retain management and employees with appropriate skills and expertise; the impact of increased taxation, changes in market, legal and regulatory conditions and in the applicable business environment, including actions of competitors; and other factors. Additional risk factors are listed in the Company's Annual Report on Form 10-K under the heading "Risk Factors." The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.
As of June 30, December 31, 20122011(unaudited)ASSETSCurrent Assets:Cash and cash equivalents$
751,111Trade accounts receivable, net of allowance for doubtful accounts of $1,209,073
and $1,232,806, respectively6,582,8557,083,354Inventories, net12,301,8548,479,710Prepaid and other current assets586,014289,326Total current assets20,684,28816,603,501Non-current inventories1,042,820920,542Property and equipment, net4,450,1153,774,140Intangible assets, net617,124656,133Goodwill728,618728,618Other assets930,520486,914Total Assets$
23,169,848LIABILITIES & STOCKHOLDERS' EQUITYCurrent Liabilities:Accounts payable$
2,654,263Accounts payable - related party567,811513,193Accrued liabilities2,409,8883,762,211Warrant derivative liability825,3892,344,516Current portion of capital lease obligations87,83533,791Current portion of long-term debt4,258,9901,632,978Total current liabilities11,755,73310,940,952Long-term Liabilities:Capital lease obligation, less current portion191,95889,580Long-term debt, less current portion6,362,1516,638,270Total Liabilities18,309,84217,668,802Commitments and Contingencies Stockholders' Equity (Deficit)Preferred stock, $.000001 par value; 5,000,000 shares authorized; no shares issued
andoutstanding--Common stock, $.000001 par value; 95,000,000 shares authorized; 42,747,457
shares issued and outstanding as of June 30, 2012 and 40,841,218 shares issued and
outstanding as of December 31, 2011 4340Additional paid-in capital50,411,60445,452,732Retained deficit(40,268,004)(39,951,726)Total Stockholders' Equity 10,143,6435,501,046Total Liabilities & Stockholders' Equity $
BACTERIN INTERNATIONAL HOLDINGS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSThree Months Ended June 30,Six Months Ended June 30,2012201120122011RevenueTissue sales
13,238,972Royalties and other94,667138,427193,719270,307Total Revenue8,208,2727,508,47515,978,27313,509,279Cost of tissue and medical devices sales2,329,4321,742,1444,188,1542,729,443Gross Profit5,878,8405,766,33111,790,11910,779,836Operating ExpensesGeneral and administrative2,319,8511,505,1654,910,6233,897,026Sales and marketing3,835,2094,331,1457,981,5528,595,426Depreciation and amortization95,20662,533214,280115,205Non-cash consulting expense(24,069)147,485304,184388,475Total Operating Expenses6,226,1976,046,32813,410,63912,996,132Loss from Operations(347,357)(279,997)(1,620,520)(2,216,296)Other Income (Expense)Interest expense(266,200)(132,879)(409,052)(498,540)Change in warrant derivative liability1,301,5767,5791,519,1277,226,385Other income (expense)42,498-194,167-Total Other Income (Expense)1,077,874(125,300)1,304,2426,727,845Net Income (Loss) Before (Provision) Benefit
for Income Taxes730,517(405,297)(316,278)4,511,549 (Provision) Benefit for Income TaxesCurrent----Deferred----Net Income (Loss)
4,511,549Net income (loss) per share:Basic
0.10Shares used in the computation:Basic42,695,35038,216,95642,121,71837,776,259Dilutive44,683,66338,216,95642,121,71843,572,293
James Carbonara, Regional Vice President
Brett Maas, Managing Partner
|SOURCE Bacterin International Holdings, Inc.|
Copyright©2012 PR Newswire.
All rights reserved